Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.
2.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608
3.

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.

Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1884-91.

PMID:
8759358
4.

Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.

Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M.

Lab Invest. 1996 Jan;74(1):33-42.

PMID:
8569195
5.
8.

Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.

Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Büschenfelde KH, Dippold WG.

Eur J Cancer. 1999 Jan;35(1):117-24.

PMID:
10211099
9.

Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement.

Marschang P, Sodroski J, Würzner R, Dierich MP.

Eur J Immunol. 1995 Jan;25(1):285-90.

PMID:
7531147
10.
11.
12.

HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.

Marschang P, Gürtler L, Tötsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP.

AIDS. 1993 Jul;7(7):903-10.

PMID:
7689323
14.

Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.

Nakamura M, Okada H, Sasaki H, Yoshida K, Kamada M, Okada N, Terada M, Ohno T.

Microbiol Immunol. 1996;40(8):561-7.

15.
16.
17.

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.

Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M.

Curr Cancer Drug Targets. 2010 Dec;10(8):922-31.

PMID:
20879979
18.

Immunization against tumor cell surface complement-regulatory proteins.

Durrant LG, Spendlove I.

Curr Opin Investig Drugs. 2001 Jul;2(7):959-66. Review.

PMID:
11757799
19.

Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.

Huang J, Gou D, Zhen C, Jiang D, Mao X, Li W, Chen S, Cai C.

FEMS Immunol Med Microbiol. 2001 Oct;31(3):203-9.

20.

Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from normal and hDAF transgenic pigs.

Bennet W, Björkland A, Sundberg B, Brandhorst D, Brendel MD, Richards A, White DJ, Nilsson B, Groth CG, Korsgren O.

Transplantation. 2001 Jul 27;72(2):312-9.

PMID:
11477359

Supplemental Content

Support Center